China's pharmaceutical companies independently develop new cancer drugs on the market

After 14 years of continuous efforts, China's pharmaceutical companies independently developed innovative oncology drug Sutaida ® (Sovantini capsule) 23 officially listed.
it is understood that Sutaida ® is a new type of oral tyrosine kinase inhibitor, has been approved by the State Drug Administration for the treatment of non-pancreatic neuroendocrine tumors.
different from traditional anti-tumor drugs, Sutaida ® has both "anti-angiogenesic" and "immune regulation" dual anti-tumor mechanisms, which not only inhibit tumor angiogenesic, but also activate the body's immune function.
Chinese Academy of Sciences academician Chen Kaixian 23, told reporters that the listing of Sutaida ® not only for China's non-pancreatic neuroendocrine tumor targeted treatment to provide drug solutions, but also shows that China's innovative drugs are cutting-edge innovative research concepts, standardized research and development processes to accelerate the benefits of Chinese patients, to the world.
" Chen Kaisan said that for a long time, China's independent research and development capacity of new drugs is weak, unable to get rid of dependence on imported drugs.
in the last decade or two, China's new drug research and development capabilities and output has made very rapid progress, from 2018 to 2020, China's independent research and development of new drugs have been approved for market.
means that China's innovation capabilities in drug research and development are rapidly improving.
Neuroendocrine Tumor (NET) is a type of tumor that originates from neuroendocrine cells and is most common in the stomach, intestines, pancreas and lungs.
, non-pancreatic NET accounts for about 90%.
Professor Wang Liwei, Department of Oncology, Renji Hospital, affiliated with Shanghai Jiao university's School of Medicine, said on the same day: "Previously, net patients had very limited treatment options, and there was an urgent need for more innovative clinical therapies to meet patients' unfinished needs."
" interview, the reporter learned that the relevant clinical research reality, Sutaida ® treatment group patients in the median non-progressed survival (PFS) significantly extended, good safety.
, according to Professor Wang Liwei, Sutaida ® is expected to lead to changes in China's NET clinical practice guidelines, which has contributed to the vigorous development of innovative drugs in China.
interview, the reporter learned that the future of Sovantini as China's innovative drug is expected to go global, for a large number of overseas patients to bring more choices and the gospel.
in December 2020, Sovantini was approved for listing in China, and the same month it began rolling applications for new drugs to the FDA, which is expected to be approved in the U.S. in 2021.
it is understood that the company will also be facing Europe to submit applications for the listing of new drugs.
(Complete)